Category Archives: Global News Feed

Montrouge, France, February 21, 2023

Excerpt from:
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET

See the original post here:
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of...

WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company’s chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical.

Read the original:
Invivyd Announces Changes to Executive Team

BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:

View original post here:
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

SYDNEY, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced that it has been issued a trademark for RECCE® by the Trade Marks Registry Intellectual Property Department in Hong Kong. This newly registered trademark strengthens the Company’s global intellectual property (IP) portfolio.

Original post:
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong, Strengthening Global IP Portfolio

Additional Capital Will Help Fund Development of PAX-101

Go here to see the original:
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.

Read this article:
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET

See original here:
MDxHealth Announces Pricing of Offering of ADSs in the United States

Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference

View original post here:
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference

NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, in accordance with French regulatory requirements, is supplementing its previous announcement of the pricing of its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representing the right to receive one ordinary share of Cellectis, nominal value €0.05 per share (the “Global Offering”), which launched and priced on February 2, 2023, at a price to the public of $2.50 per ADS as announced on February 2, 2023. The closing of the Global Offering is expected to occur on or about February 7, 2023, subject to customary closing conditions.

Read the original:
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information